Please write essays on the following basal ganglia topics (I don’t mind who does which), and be prepared to discuss (present) your topic for 15 minutes to educate and inform your colleagues. Overhead projector, whiteboard and any other aids you might need will be available.
WHAT DO WE UNDERSTAND OF THE STRUCTURE (INCLUDING MICROSTRUCTURE) AND FUNCTION OF THE BASAL GANGLIA?
1. Smith, A. D. and Bolam, J. P. (1990) "The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones." Trends Neurosci 13 (7): 259-265.
2. Smith, Y., M. D. Bevan, et al. (1998). “Microcircuitry of the direct and indirect pathways of the basal ganglia.” Neuroscience 86(2): 353-87
WHAT DO WE KNOW ABOUT THE MOLECULAR PATHOLOGY OF PARKINSON’S DISEASE?
1. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998; 4:1318-20 (article)
2.
Genetic dissection of familial Parkinson's disease. Mol Med Today. 1998:
4: 438-44. Understanding cell death in Parkinson's disease. Ann Neurol. 1998;
44(3 Suppl 1):S72-84. Review.
The synucleins: a family of proteins involved in synaptic function, plasticity,
neurodegeneration and disease. Trends Neurosci. 1998: 6:249-54 see at:
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T0V-3TDJ1TR-9&_coverDate=06%2F01%2F1998&_alid=65126684&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=4872&_sort=d&wchp=dGLbVlz-lSztz&_acct=C000010360&_version=1&_urlVersion=0&_userid=126524&md5=32ea0df528cc0d82af789ba59c0bb88b
3. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276: 2045-7 (article)
4. Protein aggregation in Huntington's and Parkinson's disease: implications for therapy. Mol Med Today. 2000: 10:387-91 see at: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T9S-417MK7K-F&_coverDate=10%2F01%2F2000&_alid=65127882&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5122&_sort=d&wchp=dGLbVlz-lSztz&_acct=C000010360&_version=1&_urlVersion=0&_userid=126524&md5=68bf3532539cffce0a00e1f028619cf5
5. A Drosophila model of Parkinson's disease. Nature. 2000; 404: 394-8 (article)
6. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. 2002; 22:2780-91 (article)
WHAT ROLE MIGHT TRANSPLANTATION PLAY AS A FUTURE THERAPY FOR BASAL GANGLIA DISORDERS?
1. Bjorklund, A. (1991). “Neural transplantation--an experimental tool with clinical possibilities.” Trends Neurosci 14(8): 319-22.
2. Dunnett, S. B. and A. Bjorklund (1999). “Prospects for new restorative and neuroprotective treatments in Parkinson's disease.” Nature 399(6738 Suppl): A32-9.
3. Dunnett, S. B., A. L. Kendall, et al. (1997). “Neuronal cell transplantation for Parkinson's and Huntington's diseases.” Br Med Bull 53(4): 757-76.
4. Fisher, L. J. and F. H. Gage (1994). “Intracerebral transplantation: basic and clinical applications to the neostriatum.” Faseb J 8(8): 489-96.
5. Freeman, T. B. (1997). “From transplants to gene therapy for Parkinson's disease.” Exp Neurol 144(1): 47-50. WHOLE ISSUE IS GOOD
6. Gage, F. H. (1998). “Cell therapy.” Nature 392(6679 Suppl): 18-24.
7. Shihabuddin, L. S., T. D. Palmer, et al. (1999). “The search for neural progenitor cells: prospects for the therapy of neurodegenerative disease.” Mol Med Today 5(11): 474-80 see at: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T9S-3XR7WPW-H&_coverDate=11%2F01%2F1999&_alid=65128862&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5122&_sort=d&wchp=dGLbVzz-lSzBV&_acct=C000010360&_version=1&_urlVersion=0&_userid=126524&md5=09e64408a404962fca9c4552eba60ac7
8. Cell replacement therapies for central nervous system disorders. Nat Neurosci. 2000 Jun;3 :537-44 (article)
WHAT IS THE POTENTIAL OF GENE THERAPY FOR THE TREATMENT OF BASAL GANGILA DISORDERS?
1. Dunnett, S. B. and A. Bjorklund (1999). “Prospects for new restorative and neuroprotective treatments in Parkinson's disease.” Nature 399(6738 Suppl): A32-9.
2. Fisher, L. J. and F. H. Gage (1995). “Novel therapeutic directions for Parkinson's disease.” Mol Med Today 1(4): 181-7.
3. Freeman, T. B. (1997). “From transplants to gene therapy for Parkinson's disease.” Exp Neurol 144(1): 47-50. WHOLE ISSUE IS GOOD
4. Olson, L. (1997). “The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications.” Trends Neurosci 20(7): 277-9.
5. Parkinson’s disease: a neurodegenerative disease particularly amenable to gene therapy. Molecular Therapy 2000; 1, 494-6 see at: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WNJ-45C0SD8-21&_coverDate=06%2F30%2F2000&_alid=65129490&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6964&_sort=d&wchp=dGLbVlz-lSztA&_acct=C000010360&_version=1&_urlVersion=0&_userid=126524&md5=f3d9083a305a252c19bebb46b2affd06
6. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A. 2002; 99: 4708-13 (article)
7. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. 2002; 22:2780-91 (article)
OMIM: alpha synuclein at http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=163890
Genes and disease at http://www.ncbi.nlm.nih.gov/disease/Parkinson.html
The Parkinson’s web at: http://pdweb.mgh.harvard.edu/
Parkinson’s disease society at: http://www.parkinsons.org.uk/
mjaw
3.xi.05